MARKET

TRML

TRML

Tourmaline Bio
NASDAQ
18.41
+1.37
+8.04%
Opening 13:16 03/14 EDT
OPEN
17.72
PREV CLOSE
17.04
HIGH
18.57
LOW
17.53
VOLUME
231.91K
TURNOVER
--
52 WEEK HIGH
48.31
52 WEEK LOW
11.87
MARKET CAP
472.08M
P/E (TTM)
-10.9622
1D
5D
1M
3M
1Y
5Y
1D
Tourmaline Bio Is Maintained at Outperform by Wedbush
Dow Jones · 3h ago
Wedbush Maintains Outperform on Tourmaline Bio, Raises Price Target to $43
Benzinga · 3h ago
TOURMALINE BIO INC <TRML.O>: WEDBUSH RAISES TARGET PRICE TO $43 FROM $42
Reuters · 5h ago
Tourmaline Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6h ago
Tourmaline Bio Price Target Raised to $50.00/Share From $49.00 by HC Wainwright & Co.
Dow Jones · 6h ago
HC Wainwright & Co. Maintains Buy on Tourmaline Bio, Raises Price Target to $50
Benzinga · 6h ago
TOURMALINE BIO, INC. <TRML.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $50 FROM $49
Reuters · 7h ago
U.S. RESEARCH ROUNDUP-Advanced Flower Capital, BRT Apartments, Xponential Fitness
Reuters · 10h ago
More
About TRML
More
Tourmaline Bio, Inc. is a late-stage clinical biotechnology company. The Company is focused on developing transformative medicines that improve the lives of patients with life-altering immune and inflammatory diseases. The Company’s initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. TOUR006 is a long-acting anti-IL-6 antibody which has properties, including a high binding affinity to IL-6, long half-life, and low observed immunogenicity. It is also developing TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration. It is focused on two strategic paths for TOUR006, the first of which it refers to as FcRn+. Its second strategic path is cardiovascular inflammation.
Recently
Symbol
Price
%Change

Webull offers Tourmaline Bio Inc stock information, including NASDAQ: TRML real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRML stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRML stock methods without spending real money on the virtual paper trading platform.